EUVIMEDEUVIMED entdecken
Crossref

Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy

Bei Tong, Sirou Grace Leong, Tunyu Jian, Guanting Niu, Yanan Gai, Xiuhua Meng, Han Lv, Xianchi Dong, Xiaoqin Ding, Jian Chen

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Bei Tong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Na…. Hauptthemen laut MEDLINE: Interleukin-2, Polyethylene Glycols, Immunotherapy, Interleukin-2 Receptor alpha Subunit. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Jiangsu Provincial Key Research and Development Program, National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While Interleukin 2 (IL2) has the capability to activate both NK and T cells robustly, its limited in vivo half-life, considerable toxicity, and tendency to boost Treg cells pose significant challenges, restricting its widespread application in cancer therapy. In this investigation, we engineered a novel IL2 variant (IL2-4M-PEG) with reduced CD25 binding activity and an extended half-life by substituting amino acids associated with CD25 binding and implementing site-directed PEGylation. IL2-4M-PEG notably amplifies effector cells over Treg cells. Furthermore, our findings reveal that IL2-4M-PEG, characterized by an extended half-life, exhibits anti-tumor effects in a mouse model. Consequently, this innovative IL2 holds the potential for enhancing combined cancer therapies in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-2Polyethylene GlycolsImmunotherapyInterleukin-2 Receptor alpha SubunitAnimalsHumansMiceCell Line, TumorNeoplasmsT-Lymphocytes, RegulatoryProtein BindingMice, Inbred C57BLFemaleMice, Inbred BALB CKiller Cells, Natural

Stichwörter der Autor:innen

Interleukin 2Site-directed PEGylationTumor immunotherapyTumor model

Substanzen

Interleukin-2Polyethylene GlycolsInterleukin-2 Receptor alpha Subunit

Autor:innen und Institutionen

  • Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China.
  • Department of Oncology, Nanjing Drum Tower Hospital, School of Life Science, Nanjing University, Nanjing, China.
  • Department of Oncology, Nanjing Drum Tower Hospital, School of Life Science, Nanjing University, Nanjing, China; Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, Nanjing, China. Electr…
  • Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China. Electronic address: dingxiao_qin@126.com.
  • Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, China. Electronic address: chenjian80@aliyun.com.

Förderung

  • Jiangsu Provincial Key Research and Development Program
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Jiangsu Provincial Key Laboratory for the Research and Utilization of Plant Resources, Chinese Academy of Sciences

Zitieren

APA

Tong, B., Leong, S. G., Jian, T., Niu, G., Gai, Y., Meng, X., Lv, H., Dong, X., Ding, X., & Chen, J. (2024). Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112359

Vancouver

Tong B, Leong SG, Jian T, Niu G, Gai Y, Meng X, et al. Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112359

BibTeX
@article{Tong2024,
  author = {Tong, Bei and Leong, Sirou Grace and Jian, Tunyu and Niu, Guanting and Gai, Yanan and Meng, Xiuhua and Lv, Han and Dong, Xianchi and Ding, Xiaoqin and Chen, Jian},
  title = {Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112359}
}
Kostenlos starten →